Beiping Miao

This paper identifies P2RY2 as a purinergic immune checkpoint that mediates eATP-driven immune evasion and adaptive resistance to immunotherapy by promoting PGE2 accumulation in the tumor microenvironment.

This study uses Dual Ribosome Profiling to reveal cell type-specific metabolic limitations in the tumor microenvironment, showing how amino acid availability affects immunotherapy outcomes.

This study identifies MI-2, a novel GPX4 inhibitor that induces ferroptosis by inhibiting GPX4 activity and promoting its degradation, showing synergistic effects with existing cancer drugs.

This study identifies a novel germline POT1 mutation (p.V29L) associated with familial non-medullary thyroid cancer and shows it causes telomere dysfunction.